These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20644113)

  • 1. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
    Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
    Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
    Hashizume M; Uchiyama Y; Horai N; Tomosugi N; Mihara M
    Rheumatol Int; 2010 May; 30(7):917-23. PubMed ID: 19639319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.
    Song SN; Iwahashi M; Tomosugi N; Uno K; Yamana J; Yamana S; Isobe T; Ito H; Kawabata H; Yoshizaki K
    Arthritis Res Ther; 2013 Oct; 15(5):R141. PubMed ID: 24286116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A; Nakazawa S; Hanabusa H
    J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.
    Noguchi-Sasaki M; Sasaki Y; Shimonaka Y; Mori K; Fujimoto-Ouchi K
    BMC Cancer; 2016 Apr; 16():270. PubMed ID: 27068103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.
    Yuzuriha A; Saitoh T; Koiso H; Mitsui T; Uchiumi H; Yokohama A; Handa H; Kojima M; Tsukamoto N; Karaswa M; Murakami H; Nojima Y
    Acta Haematol; 2011; 126(3):147-50. PubMed ID: 21757886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-
    Shu W; Pang Z; Xu C; Lin J; Li G; Wu W; Sun S; Li J; Li X; Liu Z
    Mediators Inflamm; 2019; 2019():4038619. PubMed ID: 31814801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
    Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of recombinant human erythropoietin on hepcidin mRNA expression in patients with multiple myeloma].
    Wang FD; Zhou DB; Li SL; Wang X; Zhang JP; Duan MH; Shen T; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):390-4. PubMed ID: 21518494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.
    Maes K; Nemeth E; Roodman GD; Huston A; Esteve F; Freytes C; Callander N; Katodritou E; Tussing-Humphreys L; Rivera S; Vanderkerken K; Lichtenstein A; Ganz T
    Blood; 2010 Nov; 116(18):3635-44. PubMed ID: 20679527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
    Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
    Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K; Murayama S; Ito H; Koga T
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cytokine Storm of Multicentric Castleman Disease.
    Fajgenbaum DC
    Adv Exp Med Biol; 2024; 1448():459-467. PubMed ID: 39117833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
    Sugawara E; Sato T; Amasaki Y; Katsumata K
    Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia.
    Matsumoto M; Tsujino T; Lee-Kawabata M; Naito Y; Akahori H; Sakoda T; Ohyanagi M; Tomosugi N; Masuyama T
    Circ J; 2010 Feb; 74(2):301-6. PubMed ID: 20019408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid anemia.
    Masson C
    Joint Bone Spine; 2011 Mar; 78(2):131-7. PubMed ID: 20851655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.
    Nemeth E; Valore EV; Territo M; Schiller G; Lichtenstein A; Ganz T
    Blood; 2003 Apr; 101(7):2461-3. PubMed ID: 12433676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
    Turcotte LM; Correll CK; Reed RC; Moertel CL
    Pediatr Blood Cancer; 2014 Apr; 61(4):737-9. PubMed ID: 24019247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.